Company announcement – No. 45 / 2023 U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital…
Scott Leffler Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler…
- Agreement Seeks to Leverage Linea IVT Platform to Enable Kudo Bio to Offer a Differentiated mRNA Manufacturing Capability with…
- Conference Call/Webcast Scheduled for Today at 4:30 PM ET -STONY BROOK, NY / ACCESSWIRE / December 7, 2023 /…
STONY BROOK, NY / ACCESSWIRE / December 5, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),…
The primary care facility seeks to accelerate clinical documentation while maintaining high-quality patient care and boosting overall clinic efficiencyWESTBOROUGH, Mass.--(BUSINESS…
STONY BROOK, NY / ACCESSWIRE / November 28, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),…
Lifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing…
Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer…
- Extension Increases Total Addressable Market to Include Both Conventional Non-Amplifying mRNA and saRNA -- Extension Enabled by the Company's…